# A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

> **NCT00162110** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 40 (—)

## Conditions studied

- Mucinous Gastrointestinal Adenocarcinoma

## Interventions

- **DRUG:** cetuximab

## Key facts

- **NCT ID:** NCT00162110
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 40 (—)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162110, "A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00162110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*